Cannabis Edibles for Multiple Sclerosis Spasticity

Multiple sclerosis spasticity is raised muscle tone, the stiffness that makes a leg feel set in plaster. Spasms are the sudden involuntary contractions that ride on top of it, the calf that locks at three in the morning. In the NARCOMS registry survey Rizzo and colleagues published in 2004, 16% of people with MS reported no spasticity, 31% minimal, 19% mild, 17% moderate, 13% severe and 4% total: most have some, most of it is mild, and about one in three modify daily activities because of it.

Cannabinoids have been failing the neurologist's ruler and passing the patient's for twenty years, and the position here follows from that. For someone whose baclofen, gabapentin or tizanidine does not control the stiffness, or is not tolerated at the dose that would, a titrated 1:1 THC:CBD edible is a reasonable add-on, backed by the strongest trial evidence for any cannabis medicine on this site. It does not replace the first-line drug. The benefit is in how stiffness, spasms and sleep feel to the person living in the leg, it lands in roughly one person in three, and a neurologist measuring resistance at the ankle will not see much of it. This page opens the Neurological cluster.

Do THC edibles help multiple sclerosis spasticity?

On the measure that matters to the person, yes. Every trial that made the patient's own 0 to 10 spasticity rating the primary endpoint came out positive, and the largest oral-extract trial found relief from stiffness, spasms and poor sleep in about one person in three. On the clinician's Ashworth scale the same drugs mostly failed.

CAMS, published in the Lancet in 2003, enrolled 667 people with stable MS and spasticity and treated 630 at 33 UK centres with oral cannabis extract, oral THC or placebo for 15 weeks. The primary outcome was the Ashworth scale, a clinician grading resistance while moving the limb, and cannabinoids did nothing to it. On the patients' own ratings, 61% on extract and 60% on THC reported improved spasticity against 46% on placebo. The 12-month blinded follow-up, published in 2005, then found the small objective benefit the short trial had missed, a mean Ashworth reduction of 1.82 points on THC against a slight worsening on placebo. The patients said the same thing both times.

The rulers disagree because Ashworth grades stiffness at one moment on a couch, and spasticity is a 24-hour condition whose worst hours the couch never sees. The American Academy of Neurology's 2014 review, since retired, graded oral cannabis extract effective for patient-reported spasticity, THC and nabiximols probably effective, and oral extract probably ineffective on objective measures short term. It graded spasticity-related pain apart from MS central neuropathic pain, a different symptom with its own page on neuropathic pain, and from the broader Pain cluster.

Is a 1:1 THC:CBD gummy the same as Sativex?

Same ratio, different route. Sativex, generic name nabiximols, is an oromucosal spray delivering 2.7 mg THC and 2.5 mg CBD per spray, titrated over two weeks to a ceiling of 12 sprays a day. A gummy is swallowed, so it behaves like the capsules in the CAMS and MUSEC trials rather than like the spray.

Twelve sprays is 32.4 mg THC and 30 mg CBD a day at the ceiling. The UK product information puts the median dose in the MS trials at eight sprays, about 22 mg THC, with at least 15 minutes between sprays. Each spray also carries up to 40 mg of ethanol. The UK licensed it in 2010. Jazz's 2022 annual report counted 29 markets outside the United States, the last count: Jazz sold Sativex to CNX Therapeutics on October 31, 2025, and its 2025 report records the sale without a number.

In November 2019 NICE recommended a 4-week trial of the spray for moderate to severe MS spasticity when other drugs have not worked, continued only if the person's own 0 to 10 rating has dropped at least 20%, under a pay-for-responders scheme in which the manufacturer funds the first three 10 ml vials. The committee also called much of the evidence low quality. The health service made the drug company bet on its own drug, more honesty than any gummy brand has offered.

Why is Sativex not approved in the United States?

Because the US trial measured muscle tone rather than the patient's rating. Jazz's RELEASE MSS1 trial, 68 adults, missed its primary endpoint on the Modified Ashworth Scale at Day 21 in June 2022, and Jazz discontinued the US program that year. Sativex has never been FDA-approved, and Jazz sold the product in October 2025.

Jazz had paid $7.2 billion for GW Pharmaceuticals in 2021. On June 28, 2022 it announced that RELEASE MSS1, a 68-patient crossover trial, did not meet its primary endpoint of change in lower-limb muscle tone on the Modified Ashworth Scale between baseline and Day 21. By the third-quarter report that autumn the company had, in its words, made the decision to discontinue the program. Nineteen years after CAMS, the FDA wanted a goniometer and the drug kept answering with a diary.

How much THC did the MS spasticity trials use?

MUSEC titrated swallowed capsules from 5 mg to a maximum of 25 mg THC a day over two weeks, and only a quarter of the extract group was still on the top dose at week 12. Sativex trials ran a median of eight sprays a day, about 22 mg THC. Neither is a gummy dose picked off a shelf.

MUSEC, published in 2012, randomised 279 people at 22 UK centres, 144 to oral cannabis extract and 135 to placebo, for 12 weeks. Each capsule held 2.5 mg THC standardised on 0.8 to 1.8 mg CBD, THC-dominant with CBD, one capsule twice a day to start, raised by 5 mg every three days to a ceiling of 25 mg. The primary outcome was self-reported relief from muscle stiffness: 29.4% on extract against 15.7% on placebo (OR 2.26, 95% CI 1.24 to 4.13). Relief from spasms, pain and sleep disturbance followed, sleep most strongly. And the dose story: by week 12 only 24.5% of the extract group was still on 25 mg against 69.4% on placebo.

Why the oral trials matter more to you: CAMS and MUSEC used capsules that pass through the gut and liver, where THC becomes 11-hydroxy-THC, with onset in one to three hours and a six-to-eight-hour tail. That is a gummy. Sativex is absorbed through the lining of the mouth within 15 minutes. The capsule evidence is what transfers, titration schedule included.

The spray trials fill in the rest. Collin 2007 randomised 189 people, 124 to active spray, for six weeks on the patient's daily rating, and won. Novotna 2011 used an enriched design: 572 people took the spray single-blind for four weeks, 272 improved by at least 20%, and 241 of those were randomised to spray or placebo for 12 weeks, where the spray beat placebo on the rating, spasm frequency and sleep disturbance. That is the NHS rule in trial form. The 2022 Cochrane review pooled 25 trials, 3,763 participants, 2,290 on cannabinoids: nabiximols probably reduces perceived spasticity (moderate certainty), chronic neuropathic pain is uncertain, quality of life barely moves, and discontinuation for side effects runs slightly higher.

How should you dose an edible for MS spasticity?

Start at 2.5 mg THC with equal or double the CBD in the evening, half a 5 mg 1:1 piece. Hold each step three to four days and go up in 2.5 mg steps. Above 5 mg a day, split it morning and evening. Rate your spasticity 0 to 10 every day for a week before the first piece.

It mirrors MUSEC's three-day steps. The evening dose is where the night-time spasm and the sleep benefit sit. No second piece inside two hours. This page does not endorse going past the 25 mg the trials tested. The stop rule is the NHS rule, stated as this page's own: after four weeks at a dose you tolerate, rate the week again, and if the number has not dropped 20%, stop. Standard-onset gummies over fast-acting nano, because Wana's own page lists 2 to 4 hours for its fast-acting line against 6 for a standard gummy, and the night is longer than that. Our dosing guide and dosing calculator handle the per-piece arithmetic. Three products, checked against their brand sites on September 25, 2026:

The Petra mint is the titration unit, 2.5 mg of each and forty to a tin, in four states. The Papa & Barkley gummy is the maintenance pick, a 5 mg 1:1 core with CBG riding along, and it leads our pain gummy ranking. At 20 mg a day it is four pieces, a 20-pack lasts five days, and the month runs $100 to $130. The Wyld Peach is the one to argue with: its 5 mg piece cannot take a 2.5 mg step without halving a gummy, and at 20 mg a day a ten-piece tin lasts two and a half days, $240 to $300 a month for CBD the trials never measured. Then the hemp aisle, where "nerve support" and "muscle relief" gummies sell at 0 mg THC when every positive trial on this page had THC in it. Most are hemp-derived, and the dates on our hemp ban page apply to them: cannabinoids the plant cannot naturally produce lose hemp status on November 12, 2026, and the rest of the new definition takes effect December 11.

Can you take an edible with baclofen or tizanidine?

With the prescriber knowing, and without stopping either drug. The Sativex product information calls an additive effect with baclofen theoretical and says trials did not show it, though sedation stacks in practice. Do not cut baclofen because a gummy helped: the FDA label warns of hallucinations and seizures on abrupt withdrawal.

The UK product information calls an additive effect with muscle relaxants such as baclofen and benzodiazepines a theoretical risk of more falls, not seen in the Sativex trials. Sedation stacks in practice anyway, mechanism or not. NICE's warning about severe respiratory depression is specific to baclofen combined with gabapentin and is not extended here to THC. In the SAVANT trial, 106 initial responders out of 191 were randomised, and adding the spray beat further adjustment of the first-line drugs alone. Strong CYP3A4 inhibitors raise THC exposure, ketoconazole 1.8-fold in the Sativex studies, and itraconazole, ritonavir and clarithromycin are named with it. No interaction between a gummy-sized THC dose and any disease-modifying therapy is established, and this page does not invent one. A pharmacist checks the list.

When does worse spasticity need a neurologist instead of a higher dose?

When it changes suddenly. NICE tells clinicians to look for factors that worsen spasticity before escalating drugs: pressure ulcers, bladder and bowel dysfunction and infections, poor posture or positioning, and pain. A urinary tract infection is the classic trigger, and a relapse can arrive as new stiffness. None of those respond to more THC.

The principle is NICE recommendation 1.5.25, and MUSEC shows why: the trial excluded anyone with an active infection because infection moves spasticity, and its most common serious adverse event on extract was urinary tract infection. A leg that got worse over a weekend is a phone call, and a gummy that quiets it hides the reason.

One more thing, about the fear most readers bring to THC. Notcutt and colleagues took 36 people who had been on Sativex for a mean of 3.6 years, switched half to placebo blind, and watched the placebo group fail first. The dose had not crept up in three and a half years, and the product information states that no increase in daily dosage has been observed in long-term use. The people who respond find a number and hold it, and let the neurologist keep measuring the ankle.